Articles Referencing IRWD
Loss Widens at Ironwood - Analyst Blog
4/24/2013, 4:10 pm from Zacks.com in Investing, Business, Stocks
Ironwood Pharmaceuticals, Inc. 's ( IRWD ) first-quarter
2013 loss of 87 cents per share compared unfavorably with the
year-ago loss of 34 cents per share. Results were primarily hurt... Read >>
Loss Widens at IRWD on Higher Costs - Analyst Blog
1/16/2013, 10:40 am from Zacks.com in Investing, Business, Stocks
Ironwood Pharmaceuticals, Inc.'s ( IRWD ) fourth-quarter
2012 loss of 41 cents per share compared unfavorably with the
year-ago loss of 7 cents per share. Results were hurt by... Read >>
Alkermes Maintains Fiscal 2013 View - Analyst Blog
1/9/2013, 6:40 pm from Zacks.com in Investing, Business, Stocks
Alkermes plc ( ALKS ) recently
reaffirmed its view for fiscal 2013 (ending March 31, 2013). The
company continues to expect adjusted earnings per share in the
range of $0.88-$1.02. The... Read >>
Forest Settles with Glenmark - Analyst Blog
1/9/2013, 5:00 pm from Zacks.com in Investing, Business, Stocks
Forest Laboratories, Inc. ( FRX )
recently entered into a settlement agreement with Glenmark
Pharmaceuticals Ltd., relating to its patent infringement
litigation for Bystolic (nebivolol). ... Read >>
Catalyst-Filled 2013 for Onyx - Analyst Blog
1/9/2013, 2:00 pm from Zacks.com in Investing, Business, Stocks
Onyx Pharmaceuticals, Inc. ( ONXX )
recently provided an update on its performance in 2012 and its
plans for 2013. Kyprolis Off to a Strong Start Oncology product Kyprolis, which was... Read >>
Upbeat 2013 from ViroPharma - Analyst Blog
1/8/2013, 5:29 pm from Zacks.com in Investing, Business, Stocks
ViroPharma Incorporated ( VPHM )
recently provided guidance for 2013. ViroPharma expects net
product sales between $450 million and $475 million in 2013 on a
worldwide basis.... Read >>
Cubist Reports Impressive 4Q Sales - Analyst Blog
1/8/2013, 3:43 pm from Zacks.com in Investing, Business, Stocks
Cubist Pharmaceuticals Inc. 's ( CBST )
unaudited net revenues for the fourth quarter of 2012 climbed 16%
year over year to $245.9 million, driven by strong sales of its
antibiotic... Read >>
Ironwood Winds Up Debt Offering - Analyst Blog
1/7/2013, 5:50 pm from Zacks.com in Investing, Business, Stocks
Entrepreneurial pharmaceutical company, Ironwood
Pharmaceuticals, Inc. ( IRWD )
recently announced that it has completed the offering of $175
million Linaclotide PhaRMA 11% notes. The note... Read >>
Impax Launches Opana ER Generic - Analyst Blog
1/7/2013, 2:52 pm from Zacks.com in Investing, Business, Stocks
Global Pharmaceuticals, the generic division of Impax
Laboratories, Inc. ( IPXL ),
a specialty pharmaceutical company, recently started shipping its
generic version of Endo Health... Read >>
FDA Approval for Salix Drug - Analyst Blog
1/7/2013, 12:50 pm from Zacks.com in Investing, Business, Stocks
Salix Pharmaceuticals, Ltd. ( SLXP )
recently said that the FDA has approved the company's anti-diarrhea
drug for HIV/AIDS patients. Fulyzaq (crofelemer) 125 mg
delayed-release tablets... Read >>
Watson's Generic Product Approved - Analyst Blog
1/7/2013, 11:00 am from Zacks.com in Investing, Business, Stocks
Watson Pharmaceuticals, Inc. ( WPI )
recently announced that it gained US Food and Drug Administration
(FDA) approval for its generic version of Ferring Pharmaceuticals'
Lysteda (tranexamic... Read >>
Valeant Upbeat About 2013 - Analyst Blog
1/7/2013, 9:17 am from Zacks.com in Investing, Business, Stocks
Valeant Pharmaceuticals International Inc. ( VRX )
recently provided its guidance for 2013. Valeant expects to
generate additional revenue of about $1 billion in 2012, despite a
$200... Read >>
Patent Challenge for Auxilium Pharma - Analyst Blog
1/4/2013, 6:17 pm from Zacks.com in Investing, Business, Stocks
Auxilium Pharmaceuticals, Inc. ( AUXL )
and Xstelos Holdings, Inc. ( XTLS )
recently received a notice from Upsher-Smith Laboratories, Inc.
regarding the filing of a 505(b)(2) new... Read >>
Positive Results on SGYP Candidate - Analyst Blog
1/3/2013, 4:30 pm from Zacks.com in Investing, Business, Stocks
Synergy Pharmaceuticals ( SGYP )
recently presented positive results from a phase IIb/III study on
its chronic idiopathic constipation (CIC) candidate, plecanatide.
The study met its... Read >>
Ironwood Pharma Upped to Strong Buy - Analyst Blog
1/3/2013, 2:14 pm from Zacks.com in Investing, Business, Stocks
On January 2, 2013, Zacks Investment Research upgraded
Ironwood Pharmaceuticals, Inc.'s ( IRWD )
to a Zacks #1 Rank (Strong Buy). Why the Upgrade? Ironwood Pharma has been buoyed by a... Read >>